Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Choline C 11 Injection (choline c 11 injection) is indicated for positron emission tomography (PET) imaging of patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT), or magnetic resonance imaging. In these patients, 11 C-choline PET imaging may help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation. Suspected prostate recurrence is based upon elevated blood prostate-specific antigen (PSA) levels following initial therapy.
• This summary is based on the review of five systematic review(s)/meta-analysis(es). ^[1-6]
• PSMA-targeted imaging demonstrated superior diagnostic performance in primary and recurrent prostate cancer compared to [¹¹C]choline and [¹⁸F]FACBC, though it is limited by heterogeneity in PSMA expression. 4. [¹¹C]choline PET showed high sensitivity (71-84%) and specificity (86%) in detecting local and regional recurrences post-radical prostatectomy and achieved detection rates of up to 31.3% in early recurrent prostate cancer with PSA levels <0.5ng/ml.
• In high-grade glioma, [¹¹C]choline PET demonstrated 100% sensitivity and 70-88% specificity in differentiating tumor progression from treatment-related changes.
• There is no safety information available in the reviewed studies.
• There is no population types or subgroups information available in the reviewed studies.